Moleculin Announces Grant-Funded Collaboration to Expand Understanding of New Discovery

Moleculin Biotech (NASDAQ: MBRX) a clinical stage pharmaceutical company focused on the development of oncology drug candidates, some of which are based on license agreements with The University of Texas System on behalf of the M.D. Anderson Cancer Center, announced it has entered into a collaboration with a team of scientists in Poland who have received a $300,000 research grant to expand the understanding of how Moleculin’s leading STAT3 inhibitor WP1066 and the Company’s newly discovered drug candidate, WP1732, create a blockade of transcription factor STAT3 leading to tumor cell death and immune-stimulating effects.

As quoted in the press release:

“In parallel with our current clinical trial of WP1066 and our IND-enabling work on WP1732, we also want to increase our understanding of the molecular details of the mechanism by which these drug candidates have a demonstrated ability in preclinical testing to simultaneously attack tumors directly while also stimulating the immune system to fight cancer,” commented Walter Klemp, Chairman and CEO of Moleculin. “The cutting-edge nature of our newly discovery drug candidates make it possible to attract non-dilutive research grant funding like this.”

Click here to read the full press release.